IMR Press / FBL / Special Issues / neurodegeneration_immune

New Therapeutic Avenues in Neurodegenerative Diseases: What to Expect in the Future

Submission deadline: 10 April 2024
Special Issue Editors
  • Vincent Pons, PhD
    Neuroscience Laboratory, CHU de Québec Research Center, Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec City, QC, Canada
    Interests: Alzheimer disease; macrophage colony-stimulating factor; synapses; oligodendroglia; oligodendrocyte precursor cells; cuprizoneamyloid beta protein; Alzheimer disease vaccine; neurofibrillary tangles
  • Lin-Hua Jiang, PhD
    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China; School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, UK
    Interests: TRP channels; P2X receptors; Piezo1 channels; neurodegeneration; neuroinflammation
  • Antoni Camins, PhD
    Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Spain
    Interests: Alzheimer; aging; apoptosis; neuropharmacology; epilepsy
  • Pierre-Alexandre Piec, MSc
    The Jackson Laboratory, Husson University, Bar Harbor, ME, USA
    Interests: neuroimmunology
Special Issue Information

Dear Colleagues,

We propose a special issue on new therapeutic avenues to slow, treat or control neurogenerative diseases.

Most of these diseases still have no effective treatment, despite intensive research in the field. While there have recently been some interesting developments such as Lecanemab for Alzheimer’s patients, or Relyvrio for ALS patients, much more progress is required to achieve full control of the disease.

Neurodegenerative diseases are complex because more than one factor is involved in their pathogenesis. Continual progress is being made toward the ultimate goal of effective treatment by finding new molecular pathways and targets, any by unveiling the role of certain types of cell in the pathogenic process.

The aim of this special issue is to collect the latest advances in the field by providing an ideal opportunity for authors to showcase their work and present their views. Contribution in the form of opinion, mini review/review and research articles are welcome. The subject area of this special issue is deliberately vast so that it can encompass the wide range of neurodegenerative diseases, including ALS, PD, Duchenne Syndrome, SMA to AD, MS, and Charcot-Marie Tooth disease.

Dr.  Vincent Pons, Dr. Lin-Hua Jiang, Dr.  Antoni Camins and  Pierre-Alexandre Piec
Guest Editors

immune system
SMA Duchenne Syndrome
gene therapy
cell therapy
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (1 Paper)
Back to top